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The HRB’s key initiatives in 
response to the COVID-19 
pandemic during 2020 
•   Facilitated a smooth transition to 
remote working by ensuring excellence 
in information and communications 
technology (ICT) and facilities
•   Collaborated with the Irish Research 
Council (IRC) and Science Foundation 
Ireland (SFI) to co-fund a national 
COVID-19 Rapid Response Research, 
Development and Innovation 
programme 
•   Committed to data sharing in public 
health emergencies – a development 
expedited by COVID-19 
•   Began delivering evidence products  
to inform policy and practice
•   Supported and funded Ireland’s 
participation in the REMAP-CAP 
response to the COVID-19 pandemic
•   Optimised HRB Open Research
•   Established a temporary 
National Research Ethics 
Committee for COVID-19 
research




•   Supported iHealthFacts, a new 
website to help people make 
well-informed health choices, 
particularly in relation to 
COVID-19
•  Supported Ireland’s 
participation in Solidarity, 
the international clinical 
trial to help find an 
effective treatment for 
COVID-19, launched by the 
World Health Organization 
and partners 
•  Began collaborating with the 
Department of Health and the 
Central Statistics Office to create 
safe access to COVID-19 data  
for research
•  Co-funded the REMAP-CAP 
trial, which showed that a 
common steroid improves 
recovery and survival for 
critically ill COVID-19 patients
•  Recorded further success 
for the REMAP-CAP trial, 
after it was shown that a new 
treatment using an arthritis 
drug, tocilizumab, proved 
effective for the sickest 
COVID-19 patients
•   Funded 14 additional projects 
jointly with the IRC under the 
COVID-19 Rapid Response 
Research, Development and 
Innovation programme 
•   Launched a funding call  
to establish a National  
COVID-19 Biobank
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Outcomes  
and impact  
in 2020





















11,265 patients contributing to clinical trials at the three HRB Clinical Research Facilities (CRFs),  including 4,108 patients participating in active clinical trials
421 












awards across 17 





in clinical studies 
being run through 21 
Definitive Interventions 
and Feasibility  
Awards (DIFA)
2,159active users on LINK online data system 















5 patents,  
2 spinouts and  
1  licence agreement 
for HRB-supported 
innovations
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Due to the COVID-19 pandemic, 
2020 was a year like no other for 
health research. From identifying 
the novel coronavirus to developing 
vaccines in record time, the health 
research community played  
an essential role in tackling  
the crisis. Furthermore, the 
pandemic illustrated powerfully 
how the well-being of society  
and the economy depends on the 
quality of health research.
Because of this, the HRB’s role as Ireland’s 
lead agency for health research was even 
more important in 2020, as reflected in our 
huge contribution to the national efforts to 
combat COVID-19. This included funding 
and enabling clinical trials to evaluate 
treatments, supporting research into 
medical, social and policy countermeasures, 
and providing evidence reviews to inform 
policy. 
In line with the HRB Strategic Plan (2016–
2020), Research. Evidence. Action., our 
usual work programme continued quietly, 
but no less successfully. For example, 
this included providing quality data and 
evidence to inform policy and practice 
in areas such as e-cigarettes; leading 
the way in open research and public and 
patient involvement in research; and 
continuing to support the development of 
strong, patient-focused clinical research 
infrastructure. Meanwhile, we purposefully 
continued forging alliances with European 
and international partners, providing a 
voice for Irish researchers, and helping our 
research community compete for European 
Union (EU) and international funding.
Reflecting on this challenging year, what 
stood out most was our people, who 
adapted to the ‘new normal’ with tireless 
agility, resilience and resourcefulness. 
Sincere thanks to everyone for this, and to 
our Board, whose governance remained as 
skilled and steady as ever. 
Health research delivery and impact
Key initiatives delivered during 2020 
included: 
•  Supporting COVID-19 research through 
rapid response research projects, clinical 
trials and accessible trials metadata, 
rapid and systematic reviews, and World 
Health Organization (WHO) guidelines, 
contributing to tackling misinformation 
through iHealthFacts, and launching 
National COVID-19 Biobank and Central 
Statistics Office (CSO) COVID-19 Data 
Research Hub calls
•  Establishing a National Research Ethics 
Committee COVID-19 (NREC COVID-19) to 
facilitate expedited reviews of COVID-19 
research projects, and supporting the 
Health Research Consent Declaration 
Committee (HRCDC) to ensure optimal 
coordination and streamlined responses 
in support of the NREC COVID-19 and 
requests for access to the CSO COVID-19 
Data Research Hub




Professor Jane Grimson 
Chairperson
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•  Continuing to build on investment in 
clinical trials by providing funding for the 
conduct and evaluation of healthcare 
intervention studies and to support 
clinical research coordination nationally, 
as well as planning investment of €20 
million from 2022 to 2027 in clinical 
research facilities (CRFs) on the campuses 
of university hospitals across Ireland, 
and launching calls for new clinical trials 
networks (including cancer trials)
•  Supporting researchers across the HRB 
Careers Framework through funding 
for emerging clinical and academic 
researchers and research leaders, 
and through postgraduate training for 
academic and health and social care 
professionals through the Structured 
Population and Health-services Research 
Education (SPHeRE) Phase II programme, 
Collaborative Doctoral Awards, and 
the Irish Clinical Academic Training 
programme (co-funded by Wellcome) 
•  Driving public and patient involvement 
(PPI) in HRB peer review, and co-funding 
a National PPI Network with the Irish 
Research Council (IRC) to consolidate 
national capacity for PPI in health 
research and increase the number of 
health researchers who are involving 
patients/members of the public in their 
research
•  Continuing to lead the way on Open 
Science through HRB Open Research, 
mandating HRB-funded researchers to 
develop data management plans (DMPs), 
working with F1000 and the UK’s Digital 
Data Curation Centre to enable online 
management of DMPs, and training data 
stewards in universities to assist in the 
development of DMPs
•  Supporting the management and control 
of infectious diseases via an international 
evidence review, highlighting the 
importance of cross-boundary 
cooperation in response to major disease 
outbreaks and how quarantine should 
be accompanied by financial support to 
ensure compliance, as well as informing 
Ireland’s response to COVID-19 
•  Informing Department of Health 
policy on e-cigarettes and supporting 
the Health Service Executive (HSE) 
clinical guidelines, particularly those 
underpinning new legislation to ban 
the sale of e-cigarettes to people aged 
under 18 years, based on a finding 
that e-cigarettes are associated with 
adolescents starting to smoke tobacco 
cigarettes
•  Increasing our understanding of drug 
addiction and ageing by examining 
trends in drug and alcohol treatment 
data held within the HRB National Health 
Information Systems, highlighting how 
useful routinely collected data can be for 
examining questions that are important 
for health policy and practice
•  Continuing to inform policy-makers and 
practitioners in the area of drugs and 
alcohol during the pandemic, ensuring 
that drug-related publications published 
in Ireland in 2020 were made available 
in the electronic public library, and 
developing a special repository for 
COVID-19 research, information and 
guidelines related to the same area.
€39.1m
to support 125 awards  
across 17 host institutions 
and research-performing 
organisations
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Through our funding mechanisms, the HRB:
•  Invested €39.1 million in supporting 
125 research awards across 17 host 
institutions and research-performing 
organisations 
•  Leveraged €27.9 million from other 
national and international funders for 55 
awards worth a total of €36.2 million
•  Supported 217 research jobs
•  Helped Irish researchers leverage over 
€12 million from Horizon 2020
•  Supported the recruitment of more than 
11,265 patients in 421 clinical trials and 
studies underway at HRB CRFs
•  Enabled more than 1,511 cancer patients 
to enrol in 182 Cancer Trials Ireland 
active clinical trials
•  Enabled enrolment to date of 3,662 
participants in Principal Investigator-
led trials through 21 active Definitive 
Interventions and Feasibility Awards 
(DIFAs).
More detail on these as well as other 
examples and case studies demonstrating 
what was achieved in 2020 are included 
throughout this report.
Working in collaboration 
Collaboration and partnership was a strong 
theme throughout 2020, particularly as 
the research community came together 
to tackle COVID-19. In addition to funding 
research projects under a national 
COVID-19 rapid response call by the 
research and enterprise funding agencies, 
we worked with a range of regulators, 
researchers, and health professionals 
to support clinical trials in hospitals and 
intensive care units throughout Ireland. 
2020 also marked the 10th HRB-Health 
Research Charities Ireland (HRCI, formerly 
MRCG) Joint Funding Scheme to support 
research of particular interest to specific 
patient groups, and we continued to work in 
partnership with the Road Safety Authority 
(RSA), the National Directorate for Fire and 
Emergency Management, and the National 
Office for Suicide Prevention to collect 
data to inform decision-making in these 
important areas. 
Our first online conference was also a 
collaboration. We were proud to partner 
with the HRB-Trials Methodology Research 
Network, Evidence Synthesis Ireland and 
Cochrane Ireland to investigate the concept 
of trust and truth in health research. 
From understanding misinformation and 
disinformation, to assessing the credibility 
of health claims, the conference generated 
much online conversation and attracted 
almost 400 delegates from more than 25 
countries. 
Research. Evidence. Action. 9
Branching out
In March, we established the National 
Office for Research Ethics Committees in 
partnership with the Department of Health. 
This important addition to Ireland’s research 
infrastructure will fulfil a new, independent 
role in the regulation of health research in 
Ireland. The National Office for Research 
Ethics Committees team operationalised 
Ireland’s first National Research Ethics 
Committee (NREC) as part of the national 
coordinated response to the COVID-19 
pandemic, which enabled a ‘single national 
opinion’ following an expedited and robust 
ethics review process for COVID-19 health 
research. The NREC COVID-19 returned 93 
decisions over a four-month period.
In March, we also began collaborating with 
the Department of Health and the Central 
Statistics Office (CSO) to develop safe and 
secure access to the CSO COVID-19 Data 
Research Hub for valid health research 
purposes. Central to this is the Research 
Data Governance Board (RDGB), an 
independent body acting as a central 
point for data access requests. The RDGB 
Secretariat will be provided by the Health 
Research Board (HRB) to support the RDGB 
in all aspects of its work. The process will 
be fully operational in 2021, and will help 
advance our understanding of COVID-19 
for the benefit of people’s health and 
patient care, as well as to inform and shape 
healthcare policy and planning. 
Moving forward
Our success in delivering the HRB Strategic 
Plan (2016–2020) Research. Evidence. 
Action. has laid strong foundations for the 
HRB Strategy 2021–2025: Health research 
– making an impact, which was developed 
during 2020 following extensive stakeholder 
consultation. 
This new strategy is an ambitious 
programme of work that will shape the 
future of health research in Ireland. It sets 
out how we will advance health research, 
data and evidence to benefit Ireland’s 
people, society, and economy. We look 
forward to working with our large network 
of partners to ensure that research and 
evidence are translated into important 
breakthroughs that improve people’s health, 
deliver new treatments, and inform health 
policy and practice.
Dr Mairéad O’Driscoll 
Chief Executive
Professor Jane Grimson 
Chairperson





BT Young Scientist 
Congratulations to Ben  
Loughnane from Kinsale, who  
won  both the HRB Special Prize  
and came first place in the Social 
and Behavioural Sciences Category 
Intermediate Awards at the 2020 BT Young 
Scientist & Technology Exhibition. Ben’s 
project looked at a new way to better 
estimate your risk of heart attack.
in Horizon 2020 funds and a further €4 
million for COVID-19-related projects 
through Horizon 2020 Rapid Response 
calls. The programme concluded at 
the end of 2020, and over its seven-
year duration, Irish researchers were 
awarded €84.7 million, exceeding 
the target of €80 million set in 2014; 
in addition, they participated in 111 
projects, 14 of which they led.
€8.2m
Horizon 2020 success




The HRB’s first  
online conference 
was collaborative and 
focused on trust and 
truth in health research. 
From understanding 
misinformation and 
disinformation to assessing 
the credibility of health 
claims, the conference 
generated much online 
conversation and attracted 
almost 400 delegates from 
more than 25 countries.  
Research with impact
A new edition of Health 
Research in Action 
showcased some of the 
many great discoveries and 
outcomes that the HRB 
produced, delivered and 
supported across various 
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Early life – how does it impact  
on ageing and health?
A HRB co-funded project between the 
United States of America (USA), Ireland 
and Northern Ireland began exploring 
how experiences in early life, such as 
childhood poverty and marital break-up, 
impact on ageing and health. 
New ‘Vaccines Save 
Lives’ video campaign 
Spearheaded by Dr Rachel 
McLoughlin, Professor of 
Immunology, Trinity College 
Dublin (TCD), the series of 
‘Vaccines Save Lives’ videos 
funded by the HRB educates 
parents on the importance 
of vaccinating their children, 
especially during the 
COVID-19 pandemic.
The HRB announced Dr 
Mairéad O’Driscoll as its  
new Chief Executive.  
Dr O’Driscoll welcomed her 
new role, saying: “I look forward 
to working with our research 
community in academic 
institutions and across health 
and social care in Ireland to 
deliver our new strategy, which 
will generate health benefits in 
Ireland and internationally.”
€3.7m 
invested in 12 health  
research fellowships
Health data and biomarkers for the early 
detection of dementia are just some of 
the 12 health research fellowship project 
focus areas where the HRB invested €3.7 
million in 2020.  
Dr Annalisa Montesanti, Programme 
Manager, HRB, said:
“These health research fellowships form 
part of the structured award portfolio 
that the HRB has created. When 
combined, the suite of awards offers a 
very clear career pathway that develops 
and supports health researchers at every 
stage in their careers.”
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Continued lead in public and 
patient involvement (PPI) in 
research
We began integrating public reviews  
into our funding decisions, marking 
another HRB first.
Dr Anne Cody, Head of Pre-Award,  
HRB, said:
“From now on, integrating public reviews 
into panel decision-making will be the 
norm for calls that undergo public 
review, and this step is in line with our 
published plans to strengthen PPI input 
into HRB decision-making processes.”
Fulbright-HRB Health  
Impact Awards 
The Fulbright-HRB Health 
Impact Awards forge 
connections with top US 
institutions. During 2020, the 
HRB funded three awards for 
investigators from backgrounds 
as diverse as physiotherapy, 
nursing and endodontics. 
Participation in major 
international alcohol 
policy conference
HRB researchers presented 
on several important topics 
at the Global Alcohol Policy 
Conference (four posters 
and one paper). These topics 
included the impact of alcohol 
on drowning deaths in Ireland, 
the tactics used by the alcohol 
industry to influence policy in 
Ireland, and the distribution 
of alcohol-related harm in 
Ireland.
HRB figures show 
rising cocaine use
HRB drug treatment figures 
show that cases presenting 
for cocaine treatment in 
Ireland continued rising 
between 2018 and 2019, 
with cocaine overtaking 
cannabis as the second 
most common drug people 
enter treatment for.
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New National Research Ethics  
Committee (NREC) for  
COVID-19 research
Ireland’s coordinated research response to the 
COVID-19 pandemic was supported by the ministerially 
appointed Office for National Research Ethics 
Committees, which was established in 2020 and is 
located in the HRB offices in Dublin.
Dr Jennifer Ralph James, Head of the Office of National 
Research Ethics Committees, said:
“Supporting the NREC COVID-19 team in their work was 
an essential first order of business for the new Office 
of National Research Ethics Committees, and it is a 
testament to our ambition to enable a single national 
opinion for ethics in areas of national importance.”
€7.5m 
to support new health  
research leaders
We invested €7.5 million in 
supporting five new health research 
leaders. They will deliver evidence to 
inform policy and practice across a 
broad range of areas, including the 
roll-out of Sláintecare, a reduction in 
infections and the use of antibiotics, 
and better psychosocial supports 





To increase the 
transparency of our grant 
applications process, 
we created two short 
animations that bring 
researchers through the 
journey from the moment 
they press ‘submit’ to when 
they receive their outcome 
letters. The animations 
are available on the HRB 
YouTube channel. 
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€5m 
to advance careers of  
emerging clinician scientists
The HRB invested €5 million to support 
five emerging clinician scientists to 
advance knowledge in their areas and 
translate their findings into practice, 
as well as establish themselves as 
independent investigators, become 
mentors, and develop a team-based  
and collaborative approach to research.
New HRB evidence informs 
Government policy 
position on e-cigarettes
The HRB’s evidence review 
on e-cigarette use found that 
e-cigarettes are associated with 
adolescents starting to smoke 
tobacco cigarettes, which could 
potentially lead to serious harm. 
Adolescents who had never 
smoked an e-cigarette were 
between three and five times 
more likely to start smoking 
compared to those who never 
smoked e-cigarettes. The findings 
will inform policy on e-cigarettes, 
particularly in relation to harm 
reduction.
Increase in psychiatric  
in-patient admissions of 
people under 18 years of age
HRB figures show that psychiatric in-
patient admissions of people under 
18 years of age rose from 408 in 2018 
to 497 in 2019. Depression remained 
the most common diagnosis among 
children, followed by neuroses, eating 
disorders, and schizophrenia, with 
seven in ten admissions under 18 years 
old being female.  
Drugs  
and ageing
A PhD by Dr Anne Marie 
Carew, Research Officer, HRB 
National Health Information 
Systems (pictured), using our 
datasets on drug and alcohol 
use in Ireland, highlighted 
the complexities of ageing 
and drug addiction, and how 
useful routinely collected 
data are for informing policy 
and practice.
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HRB reports continued demand  
for alcohol treatment
The HRB’s annual bulletin from the National 
Drug Treatment Reporting System (NDTRS) 
on cases of treated problem alcohol use 
in Ireland, covering the period 2013 to 
2019, reported that alcohol remains the 
most common drug that Irish people seek 
treatment for; that high levels of alcohol 
dependence already exist in people first 
seeking treatment; and that there was a 
significant rise in the number of alcohol 
cases also reporting cocaine abuse. By 
monitoring such trends, the HRB can 
provide evidence to inform more targeted 
approaches for alcohol treatment.
Success for the HRB-supported  
REMAP-CAP COVID-19 trial
A global study involving more than 200 intensive care units 
found that intravenous hydrocortisone improves recovery 
and survival for critically ill COVID-19 patients. The HRB 
co-funded the Irish arm of this trial, led by Professor 
Alistair Nichol (pictured), St Vincent’s University Hospital 
and University College Dublin. 
Dr Mairead O’Driscoll, Chief Executive, HRB, said:
“This rapid response trial was possible because of our 
long-term investment in clinical research infrastructure 
across Ireland. By having this in place, we can help deliver 
timely and relevant outcomes for patients with COVID-19.”
Building better bones  
with biology
HRB-funded research at the Royal 
College of Surgeons in Ireland is using 
tissue engineering to encourage bone 
and cartilage repair. In addition, in 
collaboration with Children’s Health 
Ireland at Temple Street, the research 
project has identified a biochemical 
factor in children’s stem cells that 
speeds up bone repair. 
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Key deliverables  
in line with  
HRB strategy  
2016–2020
1
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Key deliverables  
in line with  




























Figure 1 Core elements of HRB strategy 2016-2020
Our three focus areas and enablers are complementary and interdependent, 
and we will pursue them simultaneously throughout the period of the strategy.
The HRB Strategy 2016–2020 charts  
a clear course for what the organisation  
will do over that period.
This annual report highlights key 
achievements made during 2020 in line  
with the strategy objectives, and it 










Address the research 
needs of the Irish 
health and social  
care system 
Focus areas
As the lead national agency for health 
research in Ireland, we have a responsibility 
to invest in the future as well as to meet 
the needs of today’s health system. Great 
ideas are the basis for many advances in 
healthcare. We have defined the following 
three distinct but complementary areas 
of focus that we consider to be the most 
appropriate to lead the HRB and its 
community over the period from 2016 to 
2020 and beyond:
• Address major health challenges
• Support healthcare interventions, and
•  Address the research needs of the Irish 
health and social care system.
Enabling themes
Progress in the three focus areas will be 
enabled and maximised by policies and 
actions that affect all three of these areas. 
This will be achieved by:
•  Supporting the exceptional researchers 
and leaders we need to undertake high-
quality health research and generate 
evidence
•  Building a strong enabling environment for 
health research in Ireland and ensuring 
that we understand the outcomes 
and demonstrate the impacts of our 
investments
•  Ensuring that our policies and governance 
are robust and founded on best practices.
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Focus area 1  
 
Address major  
health challenges
2020 objectives: 
•  Support high-quality, investigator-led 
internationally competitive research
•  Develop and implement co-funding 
opportunities with international agencies 
and institutions.
Key items delivered in 2020
•  In Focus area 1, we made 55 awards. Of 
these, 41 awards were co-funded with 
other Irish and international funding 
agencies, leveraging €22.5 million of the 
total €26.1 million awarded in this area. 
Details of the 55 awards are as follows:
>  In response to the COVID-19 pandemic, 
the HRB, in collaboration with the 
IRC, made 36 awards worth €5.5 
million under a rapid response call 
for medical countermeasures, health 
service readiness, and social and policy 
countermeasures
>  Funded five awards worth almost €17.1 
million for tripartite collaboration 
under the US-Ireland Research and 
Development Partnership with SFI, 
Health and Social Care R&D Division 
(HSC R&D) Northern Ireland, and the US 
National Institutes of Health
>  Funded 10 awards worth a total of €2.15 
million (HRB contribution €1.45 million) 
under the 10th HRB-Health Research 
Charities Ireland (HRCI, formerly MRCG) 
Joint Funding Scheme
>  Participated in five joint transnational 
calls in 2020 under the HRB strategy 
for engagement in European Union (EU) 
research. These included calls in the 
Joint Programme in Neurodegenerative 
Diseases (JPND), the EU Joint 
Programme in Rare Diseases (EJP RD), 
and the ERA-Net on Personalised 
Medicine (ERA PerMed) 
>  Invested in four awards worth €4.8 
million, with the HRB contributing €1.3 
million of this total. Three of these 
awards are focused on the prevention of 
obesity in children and the prevention 
of undernutrition in older adults, while 
the fourth is focused on developing 
novel neural stimulation methods in 
neurodegenerative diseases 
•  The HRB also worked to prepare four 
new transnational calls in cancer, health 
nutrition, antimicrobial resistance, and 
neuroscience research, which will open  
in 2021.
55
awards, worth  
€26.1m, were made  
in this focus area
Research. Evidence. Action. 19
When the COVID-19 pandemic hit Ireland, the 
HRB and the research community were keen 
to respond. One of the first actions by the HRB 
was a rapid response call co-funded by the IRC, 
and under a joint initiative with SFI and the 
enterprise agencies. 
The call encompassed 
three strands: medical 
countermeasures, health 
service readiness, and 
societal and policy 
countermeasures. Following 
a high volume of Twitter 
activity, queries were 
received from potential 
applicants all over Ireland as 
well as from Argentina, the 
Central African Republic, 
Ethiopia, India, Iran, 
Portugal, Spain and the 
USA, as well as from many 
companies (which were 
signposted to the SFI call). 
Despite the extremely tight 
deadlines, 165 applications 
were submitted, far more 
than originally expected. “It 
required a huge team effort 
from the whole Directorate 
to pull together a review 
process and contracting at 
this speed,” said Dr Anne 
Cody, Head of Pre-Award, 
HRB. “Since nobody had this 
in their work programme 
and we were keen to keep 
our other calls as much on 
track as possible, a lot of 
staff chipped in, covering a 
few tasks each, ranging from 
building an application form 
to dealing with contract 
negotiations. With tight 
coordination, we were 
able to create a coherent 
result.” The first projects 
commenced on 11 May, only 
6½ weeks after the call 
opened. 
Thirty-six projects with a 
combined value of over €5.5 
million were funded. They 
ranged from understanding 
the disease course and 
immune profile of COVID-19 
in immunosuppressed 
patients, to informing the 
National Ambulance Service 
response to COVID-19, to 
providing public health 
messaging and mental health 
supports. 
“The project findings 
informed decision-
makers and contributed 
to the national response 
to the COVID-19 
pandemic.” 
Some projects are 
highlighted in a specially 
dedicated COVID-19 section 
on our website. 
Case Study 1: 
HRB supports COVID-19 Rapid Response call  
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Because it achieves the best value from 
investments in health research, the HRB 
has a longstanding commitment to 
international collaboration. By linking 
national funding programmes, it is 
possible to achieve a more efficient use of 
resources, as well as avoid fragmentation 
and duplication of efforts. 
Case Study 2: 
Driving collaborative research on the international stage
Speaking about international 
collaboration, Dr Patricia 
Clarke, Programme Manager, 
HRB said: 
“High-quality, successful 
health research relies heavily 
on collaboration. Bringing 
together researchers 
from across the world and 
pooling expertise, data and 
resources means we can 
achieve a lot more together 
than alone. That’s what we 
want to achieve through 
international co-funding.” 
In 2020, we built on our 
commitment to international 
collaboration by partnering 
with other funders across 
Europe and beyond in 
several applications under 
Horizon 2020. As a result, we 
are now partners in three 
significant international 
co-funding initiatives, 
called ERA-NETS, to tackle 
brain-related diseases, 
antimicrobial resistance 
(AMR), and translational 
cancer:
1. NEURON Cofund2 
will drive translational 
research to improve 
our understanding of 
brain diseases and their 
progression, and will 
pave the way for better 
prevention, diagnosis and 
therapy. The HRB is one 
of 25 partners from 22 
countries providing a joint 
investment of €27.7 million 
for research in this area.
2. JPIAMR-ACTION aims to 
advance our understanding 
of AMR, with 27 partners 
from 22 countries, 
including the HRB and the 
Department of Agriculture, 
Food and the Marine, 
investing a total of €26.9 
million. 
3. TRANSCAN-3 builds 
on a successful co-
funding initiative to tackle 
translational cancer 
research. This funding will 
see the HRB and 28 partners 
from 19 countries invest 
€34.4 million as a catalyst for 
growth and implementation 
of translational cancer 
research.
According to Dr Clarke:
“In 2021, the HRB will run 
joint transnational calls with 
other partners in each of 
these three areas, thereby 
enabling Irish researchers 
to compete in collaborative 
calls and co-funding for 
successful Irish partners 
to address these global 
challenges.” 
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Focus area 2  
 
Support healthcare  
interventions
2020 objectives: 
•  Support the design, conduct and 
evaluation of intervention studies
•  Facilitate coordination, enabling 
mechanisms, and national and 
international collaborations that  
improve the volume, quality, relevance 
and impact of trials and intervention 
studies in Ireland.
Key items delivered in 2020
•  In Focus area 2, we made 24 awards worth 
a total of almost €14.7 million. Details as 
follows: 
>  Made 12 awards worth €7.55 million 
through the Definitive Interventions 
and Feasibility Awards (DIFA) scheme. 
Deadlines were revised due to the impact 
of the COVID-19 pandemic. These awards 
are designed to boost academic-led 
clinical trials and interventions and to 
create a pipeline of research that can 
lead to full-scale interventions
>  Awarded funding of €1.6 million for HRB 
Clinical Research Coordination Ireland 
2020 core activities and outreach 
activities at seven HRB CRFs (three 
operational until the end of 2021, seven 
from the beginning of 2022). In addition, 
a call for a new National Clinical Trials 
Coordination Programme was launched 
>  Provided supplemental funding of 
€0.4 million for the HRB Critical Care 
Clinical Trials Network to support its 
participation in an international clinical 
trial in response to the COVID-19 
pandemic
>  Worked with the Department of Health 
and the HRB CRF at University College 
Cork (UCC) to support Irish participation 
in Solidarity, the international clinical 
trial to help find an effective treatment 
for COVID-19, launched by the WHO and 
partners. This was a randomised trial 
of additional treatments for COVID-19 
in hospitalised patients who were all 
receiving the local standard of care
>  Provided transitional funding of €3.6 
million for Cancer Trials Ireland for 2021, 
in order to allow time to development 
and launch of a new funding model for 
cancer trials in Ireland.
•  Opened a new competitive call for 
Clinical Trials Networks to be awarded 
in 2021. Clinical Trials Networks enable 
the development and delivery of a high-
quality portfolio of investigator-led trials 
with relevance to health and social care 
needs in Ireland
•  Received Board approval to establish 
a Strategic Advisory Group to work 
with the HRB in the coming years to 
enhance strategic oversight of HRB 
clinical programmes and infrastructure 
investment
•  Monitored the progress of 21 active DIFAs, 
with 3,662 participants enrolled on studies 
to date
•  Enabled more than 1,511 cancer patients 
to enrol in 182 Cancer Trials Ireland active 
clinical trials
•  Worked with the Department of Health  
to develop and launch a call to establish  
a National COVID-19 Biobank
•  Supported the participation of 11,265 
patients in 421 clinical trials at three 
HRB CRFs, including 4,108 patients 
participating in 244 active clinical trials. 
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With the support of funding 
from the HRB’s Definitive 
Interventions and Feasibility 
Awards (DIFA) 2017–2020 
scheme, NUI Galway’s D1 
Now project has developed 
and piloted an intervention 
to support self-management 
and clinic attendance among 
young adults with type 1 
diabetes (T1D), a complex 
chronic condition requiring 
intensive self-management. 
T1D is particularly 
challenging for this cohort, 
as they try to balance self-
management with their life 
stage. 
The initial objectives were 
to develop and refine 
the D1 Now intervention. 
In 2020, the team ran a 
pilot cluster randomised 
controlled trial (RCT) of the 
intervention in four hospitals 
in Dublin. Fifty-seven young 
adults participated, and 
the primary aim was to 
investigate whether the D1 
Now intervention is feasible 
and acceptable for young 
adults living with T1D, as well 
as for diabetes healthcare 
staff. 
Also in 2020, a Study Within 
a Trial (SWAT) was conducted 
as part of the pilot RCT. The 
project’s Young Adult Panel 
(YAP), who all live with T1D 
and are central to D1 Now, 
led its development. The 
YAP has 11 members who all 
act as PPI contributors, and 
the experience has been 
hugely positive for them. For 
example:
Ciara – YAP member since 
2014 said:
“I joined in the hope of 
being able to help build 
a better diabetes clinic 
experience for as many 
people as possible. Through 
the YAP, we can see the 
drive to help people. Being 
able to directly influence the 
research and help shape the 
intervention as a researcher 
is fantastic, but as a patient 
it is astronomical.”
The experience for the 
investigating team was 
equally positive, and 
the project’s principal 
investigator, Professor Sean 
Dinneen said:
“We could not have 
achieved the outputs from 
our D1 Now project without 
the voice and input of our 
YAP members. For me, this 
has been the most rewarding 
part of our entire research 
journey.”
Case Study 3: 
Public and patient involvement helps young people  
with type 1 diabetes
The D1 Now team at The Patient 
Effect documentary premiere in 
November 2019. The YAP was one 
of the PPI groups featured in the 
documentary. L-R Rosah Mangan (YAP 
member), Dr Blathin Casey, Hannah 
Dunning (YAP member), Michelle 
Lowry (D1 Now Support Worker), 
Helen Burke (Advanced Nurse 
Practitioner), Cameron Keighron (YAP 
member), Professor Sean Dinneen (D1 
Now PI) and Dr Eimear Morrissey (D1 
Now Programme Manager).
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Case Study 4: 
HRB supports global efforts to fight the COVID-19 pandemic via  
a National Research Ethics Committee (NREC) for COVID-19
In 2020, the Minister 
for Health established 
a temporary National 
Research Ethics Committee 
(NREC) for COVID-19 to 
accelerate Irish research, 
support immediate, 
evidence-based decision-
making, and contribute to 
global efforts to counter 
the pandemic. It was 
operationalised and 
supported by the National 
Office for Research Ethics 
Committees at the HRB.
According to Jennifer Ralph 
James, Head of the National 
Office for Research Ethics 
Committees:
“Hallmarks of the initiative 
were the expedited 
process, coordination 
with other health research 
bodies, namely the 
Health Research Consent 
Declaration Committee 
and the Health Products 
Regulatory Authority, and 
the Committee’s mandate 
to provide a ‘single national 
opinion’ – advantages not 
afforded by the existing 
system of local research 
ethics committees.”
Importantly, the NREC 
COVID-19 was established 
to accelerate COVID-19 
research while maintaining 
international best practice 
and standards, and its 
implementation was 
an exemplar of agile 
cross-organisational 
collaboration.”
Chaired by renowned 
infectious diseases expert 
and President of the Royal 
College of Physicians of 
Ireland, Professor Mary 
Horgan, the Committee 
comprised 19 members, 
covering a diverse range 
of expertise, skills and 
experience, including 
‘non-expert’ and PPI 
representatives. From 
April to August 2020, it 
met 16 times, and returned 
decisions on 93 applications. 
Demonstrating the value of 
the NREC COVID-19 over 
a relatively short period is 
the breadth of its impact 
in study type and location. 
Notably, approximately 
one-quarter of research 
studies approved involved 
international collaboration. 
Many important studies 
would otherwise have been 
unable  to proceed, were it 
not for the NREC COVID-19. 
In line with the commitment 
of both the National 
Office for Research Ethics 
Committees and the 
Committee to transparency, 
all meetings minutes were 
made publicly available 
online. Following the last 
meeting on 19 August 2020, 
a subcommittee of the Chair 
and Vice-Chairs continues 
to convene to meet the 
oversight and related 
responsibilities associated 
with the research approved 
by the Committee. 
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Focus area 3  
 
Address the research 
needs of the Irish health 
and social care system
2020 objectives: 
•  Support research that addresses 
questions of national relevance for 
clinical and population health practice 
and for health services management, and 
translation of the research results into 
policy and/or practice
•  Provide high-quality, timely and relevant 
data for policy, service planning and 
research through the HRB’s National 
Health Information Systems (NHIS)
•  Promote and support evidence synthesis 
and knowledge translation activities to 
help policy-makers, service planners 
and providers make evidence-based 
decisions.
Key items delivered in 2020
•  In Focus area 3, we made 12 awards 
worth €3 million. Eleven of these awards 
were co-funded, with health and social 
care partners leveraging €0.57 million. 
Details of the 12 awards are as follows: 
>  Invested €1.3 million in our Applied 
Partnership Awards scheme. A total 
of six awards were made in 2020, with 
co-funding of €0.21 million provided by 
healthcare organisations
>  Ran a COVID-19-specific call, with 
four awards under the Research 
Collaborative in Quality and Patient 
Safety Awards Scheme (RCQPS) at 
a total cost of €0.5 million (€0.25 
million cost to the HRB). This scheme 
is run jointly with the Health Service 
Executive (HSE) and the Royal College 
of Physicians of Ireland (RCPI)
>  Renewed funding worth €0.21 million 
up to 2023 to the AIIHPC Palliative Care 
Research Network for an additional two 
0.5 full-time equivalent (FTE) posts over 
three years, in collaboration with the 
HSC R&D Division, Northern Ireland  
>  Awarded Phase 2 funding of €1 million 
for the Framework for Safe Nurse 
Staffing and Skill Mix to expand its pilot 
sites into new healthcare settings, 
following a successful review of 
progress in Phase 1.
•  Provided supplementary funding for 
a Collaborative Emergency Evidence 
Response programme, through Evidence 
Synthesis Ireland and the HRB-Trials 
Methodology Research Network (TMRN), 
to support generation, updating and 
knowledge translation of COVID-19-
related evidence briefs, rapid reviews 
and systematic reviews, and WHO 
guidelines
•  Contributed to the tackling of 
misinformation on COVID-19 through 
support for the establishment of 
iHealthFacts, a website where the public 
can find credible information on all 
aspects of COVID-19 
•  Provided supplemental funding to the 
Irish Longitudinal Study on Ageing (TILDA) 
and the intellectual disability supplement 
to TILDA (IDS-TILDA) to enable COVID-
19-specific and policy-relevant research 
outputs
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•  Published five evidence reviews and 
completed four evidence briefs. The 
HRB also completed four rapid evidence 
briefs and one evidence search on 
COVID-19-related issues
•  Published four issues of Drugnet Ireland
•  Published four peer-reviewed journal 
articles based on HRB Evidence Centre 
work in 2020
•  Completed Ireland’s contractual 
requirements for the European 
Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA)
•  The librarians at the HRB National Drugs 
Library updated eight fact sheets on 
the drugs situation in Ireland, covering 
alcohol, cigarette smoking, cannabis, 
cocaine, ecstasy, opiates, sedatives, and 
drug use among young people. They 
ensured that drug-related publications 
published in Ireland in 2020 were made 
available in the electronic public library. 
In February, the librarians developed a 
special repository for COVID-19 research, 
information and guidelines related 
to alcohol and other drugs to inform 
policy-makers and practitioners working 
in this area. They also contributed 
significantly to the evidence brief, Impact 
of COVID-19 on drug services in four 
countries, for the Department of Health. 
The HRB National Drugs Library website 
had 142,052 user sessions during 2020, 
and 3,273 profile visits to its Twitter feed
•  Published four HRB NHIS national reports 
and bulletins
•  Generated four infographics, and 
produced 45 quarterly performance 
indicator reports to provide clear and 
concise information to help policy-
makers and service planners make 
informed decisions about service 
planning in the area of drugs, alcohol and 
disability
•  Completed and submitted 11 peer-
reviewed journal articles based on NHIS 
data. Six articles were published in 2020
•  Collected data on behalf of the Road 
Safety Authority (RSA), the National 
Directorate for Fire and Emergency 




for the European Monitoring 




€3m made in 
Focus area 3.
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•  We continued to be key 
contributors to evidence 
reviews, and supported 
the national response 
to COVID-19 with 
literature searches for the 
Department of Health 
•  Through a cross-centre 
project, we produced a 
special evidence brief for 
the Drugs Policy Unit in 
the Department of Health 
on the impact of COVID-19 
on drug services
•  The HRB National Drugs 
Library information 
specialists maintained 
open access to our 
online repository, www.
drugsandalcohol.ie/. Early 
in 2020 we created a 
COVID-19 web resource, 
providing a special 
collection of drugs, 
alcohol and tobacco 
publications, which 
continues to grow
•  A move to virtual 
sessions with students of 
addiction-related courses 
allowed us to connect with 
classes nationwide
•  We created LibGuides 
webpages, cataloguing 
quality resources for use 
within the HRB 
•  We collaborated with 
health librarians from 
other organisations such 
as the HSE to create an 
evidence summary service 
to assist healthcare 
professionals stay up 
to date with COVID-19 
research
•  As members of the 
Health Sciences Libraries 
Group Committee, we 
helped lead initiatives to 
support the professional 
development of health 
librarians in Ireland. 
“ Relevant organisational 
policies and procedures 
ensured effective 
communication, access 
to a secure server, and 
the provision of necessary 
equipment,” said Mary 
Dunne, Information 
Specialist, HRB National 
Drugs Library. 
“ Feeling supported and well 
informed by management, 
who recognise the 
various circumstances 
we face when balancing 
personal and professional 
commitments, enabled 
us to continue working 
seamlessly. The situation 
also revealed our 
dedication to fulfilling 
our roles as information 
professionals.
2020 created opportunities 
to demonstrate the 
value of our skills and 
contributions to essential 
policy and practice. It is 
hard to envisage the future, 
but whatever we face, we 
will adapt and rise to the 
challenge,” Mary Dunne 
added. 
Case Study 5: 
HRB information specialists – adapting practice 
during a pandemic
Information professionals work extensively 
to facilitate and promote evidence-based 
information. The fast-changing, information-
overloaded environment of the COVID-19 crisis 
highlights how necessary and urgent this work is. 
Here, the six HRB Evidence Centre information 
specialists provide examples of their work in 2020.
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Case Study 6: 
Use of HRB systematic reviews for policy in 2020
The infectious diseases 
review aimed to identify 
countries that had 
implemented overarching 
public health legislation 
to manage and control 
infectious diseases following 
the WHO International 
Health Regulations core 
capacities, and lessons 
learned through national 
experiences. 
Dr Jean Long, Head of Unit, 
HRB Evidence Centre, said: 
“Our findings show that a 
variety of implementation 
strategies were used, 
although the unifying 
element of the WHO 
International Health 
Regulations core capacities 
guided all new legislation. 
Lessons learned include 
the importance of cross-
boundary cooperation in 
response to major disease 
outbreaks. The findings 
were an early input to 
inform Ireland’s response to 
COVID-19.”
Three other evidence 
reviews helped inform 
the Department of 
Health’s policy position on 
e-cigarettes and supported 
the HSE’s clinical guidelines 
on smoking cessation.The  
main findings were as 
follows:
1.  E-cigarettes are 
associated with 
adolescents starting to 
smoke tobacco cigarettes, 
potentially leading to 
serious harm. Adolescents 
who had never smoked 
an e-cigarette were 
between three and five 
times more likely to start 
smoking compared to 
those who never smoked 
e-cigarettes. 
2.  E-cigarettes are not more 
effective than approved 
and regulated nicotine 
replacement therapies to 
help people stop smoking. 
3.  There are acute health 
effects of e-cigarettes, 
including poisonings, 
burns, and lung injuries. 
Moreover, some 
chemicals in e-cigarettes 
are thought to cause 
tissue and cell damage, 
and some may cause 
cancer in the long term. 
Commenting on the  
e-cigarettes reviews, Frank 
Feighan, Minister of State 
with responsibility for Public 
Health, Well Being and the 
National Drugs Strategy, 
said: 
“One of the best things 
we can do for the health 
of our children is to 
let them grow up in a 
smoke-free world … We 
are also banning the 
sale of e-cigarettes to 
children.” 
In 2020, the HRB Evidence Centre 
published four evidence reviews 
covering public health (one on 
infectious diseases and three on 
e-cigarettes). 
Health Research Board Annual Report 202028
Enabler A  
 
Support exceptional 
researchers and  
leaders
€14.8m
Made 84 awards  
worth €14.8m  
under Enabler A
2020 objectives: 
•  Attract the best people to health 
research by supporting excellent PhD 
training programmes
•  Provide opportunities for career 
development for postdoctoral 
researchers and emerging investigators. 
Work with higher education institutions 
(HEIs), Hospital Groups, and the HSE to 
identify, develop, and support leaders in 
health research
•  Work with national and international 
partners to facilitate training and 
exchange opportunities that address 
skills gaps.
Key items delivered in 2020
•  Under Enabler A, we made 84 awards 
worth €14.8 million. Details as follows:  
>  Awarded 57 Summer Student Scholarships, 
worth a total of €0.13 million 
>  Made 12 awards under our Postdoctoral 
Fellowships scheme, with a combined 
value of €3.7 million: seven for the 
Postdoctoral Fellowships – Applying 
Research into Policy and Practice; 
and awards for the Clinician Scientist 
Postdoctoral Fellowships 
>  Supported five awards, to the value 
of €5 million, for the HRB Emerging 
Clinician Scientist Awards for health 
practitioners transitioning towards 
research independence 
>  Made five Research Leader Awards, to 
the value of €5.7 million, to promote 
‘actionable knowledge’ in research areas 
of strategic relevance to health policy, 
health delivery and/or clinical practice 
in Ireland
>  Through the Fulbright-HRB Health Impact 
Awards, provided an opportunity for 
three Irish health researchers to take 
placements of three to six months to 
develop collaborations with US colleagues. 
The total funding was €0.3 million
>  In collaboration with the College of 
Anaesthesiologists of Ireland, we supported 
intake of a PhD cohort to the Irish 
Clinical Specialty Fund, through the HRB/
Wellcome Trust, to the value of €1 million 
>  Provided supplemental funding 
of €0.345 million for 2021 for the 
Structured Population and Health-
services Research Education (SPHeRE) 
Phase II programme, to facilitate 
development of a new call in 2021.
•  Opened a new call for the Collaborative 
Doctoral Awards in Patient-focused 
Research scheme for thematic cohorts 
integrating health and social care 
professionals with academic health 
researchers. Awards will be made in 2021
•  Through the HRB Irish Clinical Academic 
Training (ICAT) Programme (established 
with Wellcome), we recruited the fourth 
cohort of new doctors to participate in  
a PhD training programme for clinicians 
•  Completed successful interim reviews of 
the Structured Population and Health-
services Research Education (SPHeRE) 
Phase II programme and also of the 11 
Emerging Investigator Awards made in 2017
•  Prepared a successful co-funded 
application with the IRC for a Marie Curie 
postdoctoral training programme in 
public health emergencies.
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Case Study 7: 
HRB-funded translational research improves the lives  
of people with diabetes
Dr McHugh (pictured), who 
is a lecturer and health 
services researcher in the 
School of Public Health at 
UCC, is a 2015 recipient 
of a HRB DIFA for her 
research on Improving 
Diabetes Eye-screening 
Attendance (IDEAs). Initially 
supported by a Fulbright-
HRB Health Impact Award, 
Dr McHugh spent several 
months working with Dr 
Byron Powell, a leader in 
implementation science 
at UNC Gillings School 
of Global Public Health, 
University of North Carolina.
 
Dr McHugh returned 
home with expertise in 
implementation science 
(the scientific study of 
how effective, evidence-
based interventions can 
be implemented in routine 
healthcare to make a 
difference to people’s lives), 
and since then, she and her 
team have been exploring 
how to help people with 
diabetes overcome barriers 
to attending regular eye 
screening, with the aim of 
increasing the number who 
take part. 
“Studies have 
shown that there 
can be practical 
and psychological 
barriers to people 
not attending,” said 
Dr McHugh. “This 
might be because the 
appointment is at an 
inconvenient time or 
location. People might 
also fear what the 
screening could find.”
The intervention was 
delivered at eight general 
practices across Ireland 
and involved staff checking 
patient records on eye 
screening attendance, and 
sending reminders to those 
who had not attended 
and providing information 
leaflets about eye screening. 
Following evaluation 
and analysis of the pilot 
intervention, Dr McHugh 
and her team found that 
the IDEAs intervention 
was feasible to deliver in a 
primary care setting and 
was acceptable to both 
health professionals and 
people with diabetes. The 
trial results indicated a 
positive impact on eye 
screening uptake, and a 
follow-on definitive trial 
will determine whether 
the refined intervention 
improves uptake and is 
cost-effective.
The HRB is committed to health research 
that translates into policy and practice. In 
2020, our funding of Dr Sheena McHugh 
furthered this commitment with the 
successful piloting of an intervention for 
people with diabetes. 
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Case Study 8: 
HRB embeds DORA principles into grant review process
DORA’s principles align 
neatly with many of our own, 
particularly regarding our 
research career frameworks 
and championing of open 
research. In 2020, that 
alignment grew as we placed 
an emphasis on integrating 
the DORA principles into 
our grant review process in 
three key ways:
1.  Restructuring our 
narrative-based CV format
2.  Assessing its effectiveness 
in the review process and 
in terms of the applicants’ 
experience 
3.  Further emphasising 
transparency in research 
assessment.
The narrative-based CV 
aims to recognise the 
diversity of researchers 
and provide peer and 
panel reviewers with more 
information on the value, 
quality, and potential impact 
of the applicant’s work, as 
well as their suitability and 
relevance to the funding 
scheme. In all research 
careers funding schemes, 
applicants must include 
a personal statement and 
address the following:
•  Contribution to knowledge
•  Contribution to training 
and career development 
of other researchers
•  Contribution to the wider 
research community and 
society.
Dr Annalisa Montesanti 
(pictured), Programme 
Manager, HRB Strategy and 
Funding Directorate said: 
“Importantly, we emphasise 
to reviewers that when 
assessing researchers, 
they should focus on the 
content, quality and impact 
of the research outputs 
in the research field and/
or in policy and practice. 
We provide this guidance 
through written guidelines, 
presentations at panel 
meetings, and in review 
forms.”
The HRB is now assessing 
the effectiveness of the 
narrative-based CV format 
in certain funding schemes, 
to further refine its 
approach and assess if it is 
suitable for funding schemes 
that are not research 
career focused. Preliminary 
results demonstrate the 
importance of using 
bottom-up feedback to 
refine and improve top-
down responsible research 
assessment policies and 
practices.
Published in 2012 and signed by the HRB in 
2017, the Declaration of Research Assessment 
(DORA) is a global initiative targeted at research 
funders, publishers, research institutes and 
researchers, with a vision to advance practical 
and robust approaches to research assessment 
globally and across all scholarly disciplines.
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Enabler B  
 
Build a strong  
enabling environment
2020 objectives: 
•  Work with the Department of Health and 
key stakeholders to shape the national 
research agenda in relation to health and 
social care 
•  Provide leadership to shape the review, 
conduct, and governance of research
•  Contribute to, and benefit from, 
international developments in policy, 
regulation, and legislation relevant to 
health research and healthcare in Ireland
•  Invest in research infrastructure to 
promote excellence, critical mass, and 
coordination to support HRB strategic 
focus areas and the wider health 
community
•  Support Irish health researchers to 
participate in Horizon 2020 (H2020) and 
other European research programmes.
Key items delivered in 2020
•  Under Enabler B, we made three awards 
worth €5.5 million. Details of these awards 
are as follows:
>  Provided funding of €0.6 million to 
support the core activities of Health 
Research Charities Ireland and the 
Irish Platform for Patient Organisations, 
Science and Industry.
•  Awarded €4.9 million for a PPI Ignite 
Network, co-funded by the IRC and the 
network’s lead sites. The award recipients 
include 7 universities, 10 national partners, 
and 54 local partners 
•  Issued an open call for the funding of CRFs/
centres supporting the infrastructure, 
governance, and the skills and expertise to 
enable high-quality, safe, and compliant 
clinical trials and other interventions. 
Awards will commence in 2021
•  Worked with partners to advance 
the development of research data 
infrastructure, access, linkage and sharing 
through the following activities:
>  Worked with the Department of Health 
and the CSO to develop a process to 
enable secure access to HSE health data 
held in the CSO COVID-19 Research Hub. 
Applications for access will be accepted 
from 2021
>  Became a partner, along with the 
Department of Health and the HSE, in 
EU PHIRI-COVID, which aims to facilitate 
and support open, interconnected, and 
data-driven research through the sharing 
of cross-country COVID-19 population 
health data.
•  In partnership with the Department of 
Health, the HRB committed to participate 
in a Joint Action Towards the European 
Health Data Space (TEHDAS) project 
that will focus on the governance, data 
quality and infrastructure of health data in 
Europe required for digital transformation 
in health and care 
•  Actively promoted PPI in research. This 
involved:  
>  Working with the five PPI Ignite Awards 
recipients to coordinate their capacity 
building for PPI in research in HEIs 
>  Including public reviews in three schemes 
(two postdoctoral fellowships and one 
DIFA) and incorporating them into the 
selection process for the first time 
>  Appointing PPI members to two selection 
panels (PPI Ignite Network and Research 
Collaborative in Quality and Patient 
Safety).
•  Took a leadership role to deliver a number 
of Open Science Research initiatives in 
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93
decisions on applications 
for ethics approval were 
returned by the NREC 
COVID-19.
Ireland. These included: 
>  Jointly chairing the National Open 
Research Forum (NORF) with the 
Higher Education Authority (HEA) and 
participating in a national landscape 
mapping exercise to be published in 2021
>  Chairing a working group to develop 
a Framework for Research Integrity in 
Collaboration Agreements, on behalf of 
the National Forum on Research Integrity
>  Publishing a Nature Commentary titled 
Research integrity: nine ways to move 
from talk to walk as an output from the 
SOPs4RI EU project, in which the HRB is 
a partner 
>  Ensuring that HRB Open Research was 
fully used to both publish and curate 
COVID-19-relevant publications from 
Irish researchers, and introduced 
mandatory publication of research 
protocols by recipients of the HRB 
co-funded national COVID-19 Rapid 
Response call
>  Publishing a new policy that requires 
HRB-funded researchers to develop data 
management plans (DMPs) to consider 
how data are collected, stored, managed, 
and shared throughout the life cycle of 
their research projects
>  Working with F1000 to enable on-line 
preparation, review and publication of 
DMPs to support a new policy on the 
management and sharing of research.
•  Facilitating and co-funding an innovative 
pilot training programme for professional 
data stewards in HEIs and Cancer Trials 
Ireland, coordinated by the GO FAIR 
International Support and Coordination 
Office. This pilot programme is ongoing 
and the new data stewards will work 
with successful HRB Investigator-Led 
Project Award recipients and Emerging 
Investigator Award recipients on the 
development of DMPs. Continued to 
increase transparency of HRB award 
selection processes by inviting external 
observers to panel meetings and by 
publishing the names of panel members 
on the HRB website 
•  Published an annual report on the gender 
breakdown of applicants and award 
recipients, and also on panel membership, 
which showed a slightly higher number of 
female applicants and award recipients, 
and well-balanced panels
•  Established the Secretariat of the National 
Research Ethics Committees (NREC), 
which in its first year: 
>  Convened a COVID-19 NREC who 
returned 93 decisions on applications for 
ethics approval
>  Worked to establish an NREC for 
Clinical Trials (NREC-CT) and an NREC 
for Medical Devices (NREC-MD), to be 
launched in 2021
>  Published a paper titled ‘Implementing 
a national approach to research ethics 
review during a pandemic – the Irish 
experience’ on HRB Open Research, 
which is currently undergoing open peer 
review .
•  Participated in a number of EU policy 
partnerships as follows: 
>  The International Consortium for 
Personalised Medicine (ICPerMed), 
a consortium of EU funding bodies 
established by the European Commission 
under the H2020 programme
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€8.2m
leveraged by Irish 
researchers in funding 
from H2020 programmes
>  The ERA-NET Cofund in Personalised 
Medicine (ERA PerMed) which fosters 
the implementation of the ICPerMed 
Action Plan
>  The Coordination and Support Action 
TO-REACH, which is developing a 
strategic research agenda for health 
systems research to identify more 
effective and sustainable ways to 
organise, manage, finance, and deliver 
high-quality care to European citizens
>  The CSA SOPs4RI EU project, which is 
creating a toolbox to support and guide 
research-performing organisations 
(RPOs) and research funding 
organisations (RFOs) in fostering research 
integrity and consequently preventing, 
detecting and handling research 
misconduct.
•  Contributed to the health perspective in 
preparations for Horizon Europe, the EU 
Framework Programme 2021–2027
•  Supported Irish researchers to compete 
successfully for EU funding: 
>  Irish researchers leveraged €8.2 million in 
funding from H2020 programmes in 2020
>  In addition, Irish health researchers 
leveraged €4 million for 11 research 
projects resulting from two COVID-19 
rapid response calls launched in 2020
>  20 Irish projects successfully competed 
for funding in the H2020 Health 
Challenge, with one project being led by 
an Irish researcher. Highlights include: 
-  A project on the scale-up and transfer 
of digital integrated care solutions to 
enable patients to proactively self-
manage their chronic diseases is being 
led by Trinity College Dublin (TCD) 
-  University College Dublin (UCD) and 
Dublin City University (DCU) are 
partners in a project on streamlined 
geriatric and oncological evaluation 
based on leveraging digital technology 
for holistic patient-oriented healthcare 
management to improve the healthcare 
management and outcomes of older 
co-morbid patients
-  The National Rehabilitation Hospital 
(NRH) is a partner in a project on a 
remote rehabilitation service for 
isolated areas, a flexible and scalable 
value-based model of care, organised 
around self-management, or self-care, 
of rehabilitation at home, designed 
from a tailored integrated care model 
which optimises the quality of care and 
the use of clinical resources
-  The use of artificial intelligence for the 
care of amyotrophic lateral sclerosis 
and multiple sclerosis patients is a 
project involving ECHAlliance Company 
Ltd as a partner
-  A patient-centred biopsychosocial 
blended collaborative care pathway for 
the treatment of multi-morbid elderly 
patients, with the Royal College of 
Surgeons in Ireland (RCSI) and Intrigo 
Limited as partners
-  A European consortium, in which NUI 
Galway is a partner, for communicating 
reliable and accessible information 
on gene and cell-based therapy 
development to various European 
stakeholders including patients, the 
public, and healthcare professionals.
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Case Study 9: 
Underpinning Ireland’s participation in global 
COVID-19 clinical trials
“While the interim results did not deliver 
new treatments for COVID-19, it’s imporant 
that we also understand what doesn’t work, 
so that patients don’t receive treatments 
unnecessarily. Crucially, Ireland is now part of 
a global infrastructure to collaborate on trials 
for other potential COVID-19 treatments.”
For over a decade, the 
HRB has taken a deliberate 
and strategic approach to 
developing Ireland’s clinical 
research infrastructure, in 
order to ensure that health 
research improves people’s 
health, patient care and 
health service delivery. 
We built this network 
of facilities and trials in 
collaboration with the HSE, 
health professionals, and 
the research community, 
and when the COVID-19 
pandemic struck, the value 
of this investment was 
realised. 
Because we had the 
infrastructure in place, 
Ireland could participate in 
Solidarity, the international 
clinical trial to help find 
an effective treatment for 
COVID-19, launched by the 
WHO and partners. Results 
found that none of the 
four treatments evaluated 
improve 28-day mortality, 
initiation of ventilation, or 
duration of hospital stay 
among patients admitted  
to hospital. 
Speaking about the trial, Dr 
Mairead O’Driscoll, Chief 
Executive, HRB, said:
“While the interim results 
did not deliver new 
treatments for COVID-19, 
It’s important that we also 
understand what doesn’t 
work, so that patients 
don’t receive treatments 
unnecessarily. Crucially, 
Ireland is now part of a 
global infrastructure to 
collaborate on trials for 
other potential COVID-19 
treatments.” 
Critically ill patients with 
COVID-19 are less likely 
to die and will spend less 
time in intensive care when 
treated with arthritis drug 
tocilizumab. These were 
the findings of another 
international trial (REMAP-
CAP) which we provided 
funding for in Ireland, and 
which was led by Professor 
Alistair Nichol, St Vincent’s 
University Hospital and 
University College Dublin.   
Commenting on the REMAP-
CAP trial, Dr O’Driscoll said:
 
“Through this research, we 
now understand better how 
to treat the sickest patients 
with COVID-19, improving 
patient outcomes and 
decreasing time spent in 
ICU, which in turn reduces 
pressure on critical care 
services. Again, this rapid 
response trial was possible 
because of our long-term 
investment in clinical 
research infrastructure, and 
specifically a clinical trials 
network in critical care. By 
having this in place, Ireland 
could act quickly as part 
of a global response for 
COVID-19 treatments in 
ICU.”
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Case Study 10: 
The Health Research Consent Declaration Committee and its 
Secretariat: A year in review
The HRCDC is tasked with 
making consensus-based 
decisions in the interests 
of patients and the public 
regarding use of their 
personal data without 
explicit consent for health 
research. The HRCDC 
Secretariat service provided 
by the HRB supports the 
HRCDC in all its work, 
acting as its central point 
of contact for the research 
community. 
Dr Emily Vereker, 
Programme Manager, 
HRCDC Secretariat, said: 
“The HRCDC convened an 
unprecedented 17 times in 
2020. Responding to the 
COVID-19 pandemic, our 
processes were temporarily 
integrated with the 
National Research Ethics 
Committee for COVID-19 
to deliver independent, 
rapid decisions for consent 
declarations and ethics 
approval for COVID-19-
related health research. 
Fifty-eight per cent of 
applications to the HRCDC 
were related to COVID-19.”
In 2020, the HRCDC made 
34 consent declarations, 
31 of which had specific 
conditions attached to 
enhance data protection 
safeguarding measures 
such as transparency.  
Importantly, the HRCDC 
views the inclusion of 
patients and the public in 
research as an important 
data protection safeguard 
to ensure that their 
perspectives are considered 
where consent cannot be 
obtained.
In 2020, the Secretariat 
engaged with several key 
stakeholders. For example:
•  the National Office 
for Research Ethics 
Committees on a seamless, 
integrated COVID-19 rapid 
review process
•  the HSE on the revision 
and development of the 
National Consent Policy
•  Department of Health, 
the HSE, and the HRB 
to develop guidance 
on recent amendments 
to the Health Research 
Regulations. 
Dr Vereker added: 
“2021 will see us engaging 
with new stakeholders 
and continuing to support 
health research policy and 
governance. International 
stakeholder engagement will 
also be an important focus, 
in order to understand 
how developments around 
trusted health data and 
sharing may influence the 
business of the HRCDC and 
Health Research Regulations 
more generally.”
In 2020, the Health Research Consent Declaration 
Committee (HRCDC) continued its important 
role within the health research regulatory 
environment. The 17-member committee is widely 
representative of the health research community, 
with three members representing patients, carers, 
and the public.
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2020 objectives:
•  Ensure a high-performing working 
environment built on innovation, 
adaptability, and teamwork 
•  Enable transparent and accountable 
decision-making based on the best 
possible information
•  Ensure that HRB systems and processes 
are robust, flexible, and scalable 
•  Enhance recognition of the values of 
health research and the HRB’s role 
nationally and internationally.
Key items delivered in 2020 
•  Extended ICT infrastructure and office fit-
out to an additional floor in Grattan House 
to accommodate the new National Office 
for Research Ethics Committees (NREC) 
•  Migrated staff intranet and data to a cloud 
environment
•  Onboarded cloud-based systems such as 
Zoom and DocuSign to enhance remote 
working capabilities
•  Completed cyber training for all staff
•  Completed health and safety training for 
all staff
•  Completed home office fit-out for all staff
•  Drafted return-to-work procedures and a 
COVID-19 Standard Operating Procedure 
(SOP) to give guidelines to office-based 
staff during the pandemic
•  Appointed a COVID-19 representative 
to enforce procedures laid down in the 
COVID-19 SOP and Return to Work Safely 
Protocol
•  Created a suite of web and social media 
promotional material to support roll-out 
of COVID-19 rapid response projects
•  Developed a new brand and visual identity 
for NREC
•  Hosted ‘Truth and trust in health 
research’, a national conference online,  
in collaboration with HRB TMRN, Evidence 
Synthesis Ireland, and Cochrane Ireland
•  Supported the development of the HRB 
Strategy 2025 and the strategy publication 
HRB Strategy 2021–2025: Health 
research – making an impact and related 
promotional materials in preparation for 
the launch in 2021
•  Delivered recruitment outcomes and  
an approach which ensured that 
resourcing and recruitment solutions  
were flexible, agile and responsive to 
evolving business needs
•  Ensured that our Human Resources 
(HR) team focused on a culture of 
equality, diversity, inclusion and disability 
awareness in all aspects of the HRB
•  Delivered a framework that strategically 
aligns performance management, mobility, 
talent management, diversity, promotion, 
recruitment, learning and development, 
as well as other relevant HR policies, in 
order to facilitate the matching of skills, 
expertise and experience to roles
•  Managed the final year of our five-year 
multiannual budget portfolio totalling 
€254 million
•  Ensured financial oversight of more than 
325 active research awards
•  Developed our financial processes 
and financial management system to 
become effectively paperless without 
compromising our product for both 
internal and external stakeholders.
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Case Study 11: 
Excellence in ICT gives HRB a head start in remote working
2020 was a working year 
like no other, and in March 
we began working from 
home. Such a transition 
is challenging for any 
enterprise. But, fortunately, 
ours was smooth due to the 
expertise and agility of our 
ICT and Facilities team. Key 
to this was foresight and a 
progressive approach to 
how we work. 
“We were already moving 
towards workplace flexibility 
long before COVID hit,” 
said Liam Sinnott, ICT and 
Facilities Manager, HRB. 
“Key was the decision to 
phase out desktops in 
favour of laptops. This is 
essential for any successful 
disaster recovery plan. But 
we were also cognisant of 
a general culture change 
in how people work, with 
more remote work on 
mobile devices, so this also 
informed our decision. 
Thanks to this, we had the 
basic infrastructure in place 
for the sudden transition.”
Once it became clear that 
the transition was long term, 
there were more issues to 
resolve, such as ensuring 
VPN access for staff and 
enabling video conferencing 
and electronic document 
signatures. While these 
issues could be resolved 
with software acquisitions, 
Facilities required more 
practical solutions. For 
example:
•  Preparing the office for a 
safe return to work
•  Providing staff with home 
office furniture
•  Providing staff with 
stationery and IT 
peripherals such as 
monitors
ICT and Facilities achieved 
this with great efficiency, 
notifying staff of all new 
processes via regular email 
and live Zoom updates, 
as well as a dedicated 
COVID-19 section on our 
intranet. Commenting on 
this impressive transition to 
remote working, Dr Mairead 
O’Driscoll, Chief Executive, 
HRB, said: 
“2020 was a year of many 
outstanding achievements 
for the HRB. We contributed 
hugely to Ireland’s efforts 
to combat COVID-19 
alongside our usual work 
when we were challenged 
collectively and individually, 
as well as personally and 
professionally. This would 
not have been possible 
without our ICT and 
Facilities team. That we 
could pivot so quickly and 
so efficiently is a testament 
to their expertise and 
professionalism.”
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Case Study 12: 
Boardroom to Zoom: Transitioning to remote recruitment, 
induction and wellness 
1)  Remote recruitment: 
The HRB hired nine 
staff via Zoom during 
2020. Commenting on 
remote recruitment, 
D’Arcy Donnelly, HR 
and Organisational 
Development Manager 
(OD), HRB said: 
“Remote interviewing has 
pros and cons. There are 
the inevitable technical 
issues and sense of personal 
disconnect. On the upside, 
it’s easier for people to 
attend interviews without 
needing long periods of 
leave. It’s also easier to 
assemble interview panels. 
Ultimately, things balanced 
out, and we’re confident we 
still made the right hires.”
2)  Remote induction: 
Our annual, organisation-
wide induction was 
conducted remotely for 
the first time in 2020 
on Zoom, and proved a 
great success. Particularly 
popular were the live 
sessions allowing staff 
interaction – not quite 
the real world, but the 
next best thing. 
3)  Remote health  
and well-being: 
Health and well-being 
is always important, but 
even more so in 2020, 
given the new challenges 
we faced. The ways Mr 
Donnelly and his team 
addressed this include:




in our induction process
•  Supporting our Sports 
& Social team to take 
an active role through 
various initiatives for 
online fun and socialising
•  Encouraging open 
dialogue with leadership 
to support varying 
personal needs and 
workload management. 
The last word goes to 
remote hire Martha 
Connolly, HRB 
Communications Officer, 
who joined the organisation 
in November 2020: 
“I’m often asked what the 
experience of interviewing 
for and starting a new 
role was like remotely. My 
honest answer is I haven’t 
found it any more difficult. 
This is down to the culture 
of the HRB, particularly 
our emphasis on open 
dialogue with management. 
I’ve always felt welcomed, 
psychologically safe, and 
supported.”
The switch to remote working in 2020 
posed unique challenges for Human 
Resources (HR). Chief among these are 
the questions of: How do you hire people 
you cannot physically meet? How do you 
induct new hires remotely? And how do 
you ensure well-being when everyone is 
stressed and siloed?  Here we outline how 
we overcame these challenges. 
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Appendix A
List of HRB publications in 2020
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Board, Dublin.
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Research. Evidence. Action. 41
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Appendix B
List of HRB awards made in 2020 to principal investigators 
PROJECTS AND PROGRAMMES










The effect of After 
Action Review in 
enhancing safety culture 
and second victim 
experience and its 
implementation in an 
Irish hospital
Royal College 























Dr Sinead Smith €171,907
Maximising the quality 
of stroke care in Ireland 
– Development of a 
National Stroke Audit
Royal College 




Professor Anne Hickey €239,998
Enhancing healthcare 
transition and 
longitudinal care for 
adolescents and adults 






Dr Deirdre Desmond €148,188
Meeting the challenge 
of childhood obesity 
treatment in Irish 
healthcare: Generating 
data to facilitate action
Royal College 




Dr Grace O'Malley €239,808
5th Annual HRI Public 







Dr Jonathan Salsberg €2,000
Retina 2020 Young Vision 







Dr Laura Brady €5,000








Professor Geraldine Boylan €9,958
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Irish Pain Society 








Professor Brian McGuire €4,650
Using a back-calculation 
model to estimate the 
scale of asymptomatic 
Covid-19 prevalence 
by age and determine 
the critical threshold 
of available susceptible 









Professor Catherine Comiskey €96,340
Using Telehealth to 
enhance management 
of vulnerable groups 









Professor Orla Hardiman €199,965
Assessing public trust 
and compliance with 









Professor Finian Buckley €138,355
Contract tracing during 
the COVID-19 outbreak: 
Enabling rapid learning 
from experiences 
and exploring the 









Dr Aoife De Brún €125,139
Children as innovators – 
harnessing the creative 
expertise of children to 










Dr Suja Somanadhan €198,693
Assessing and 
protecting the mental 
health of the nation 










Dr Philip Hyland €63,350
Impact of COVID-19 













Dr Christine Linehan €62,858
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Dr Ciara Greene €180,727
Crisis coping for 
marginalised youth: 












Professor Pat Dolan €194,299
Creating an evidence-
based toolbox for 
targeted public 
health interventions 















Professor Catherine Darker €191,116
An investigation 
of psychological 
responses to COVID-19 
in healthcare workers 
during the delay and 
mitigation phase of 
disease management: 










Professor Donal Fortune €175,013
A remote self-
directed psychological 
intervention for the 
public in response to 










Dr Tom Burke €134,455
SABS-TILDA: SARS-
CoV-2 specific 
AntiBodieS in The Irish 
Longitudinal Study 
on Ageing (TILDA): an 
opportunity to assess 
COVID-19 rates and 










Dr Nollaig Bourke €199,875
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patient recovery and 
reducing disability after 













Dr Katarzyna Whysall €199,621
Modelling the entwined 










Dr Dipto Sarkar €111,040
Altered lives in a time 
of crisis: Preparing 
for recovery from the 
impact of the COVID-19 













Defining the disease 
course and immune 

























Dr Emma Nicholson €106,408
A Rapid Resource 
Repository for Health 
Professionals (RRR-HP): 
An online and social 
media individualised 
support intervention 
for return to practice, 
reassigned and new 
to practice nursing 










Professor Alice Coffey €199,647
Development of a 
rapid, highly sensitive, 
handheld Raman-based 
device for detection 













Professor Gerard Wall €199,754
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Dr Sinéad Smyth €123,370
Guidelines for 
communicating cases 
and deaths related to 























Professor James O'Donnell €199,036


















determinants of social 












Dr Gerard Molloy €148,745
World problem, 
national solutions? The 
impact of national past 










Professor Sinisa Malesevic €185,340
Models of family 










Professor William Molloy €66,394
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Rapid response and 


















Dr Siobhan Masterson €109,188
Professional identity 
formation of junior 
doctors during the 
COVID crisis, the role of 










Professor Martina Hennessy €202,382
COVID-19: Estimating 
the burden of 
symptomatic disease in 
the community and the 
impact of public health 
measures on physical, 










Professor Ivan Perry €199,945
Maximising social 
solidarity and trust in 
public health messaging 










Professor Orla Muldoon €152,847










Professor John Lambert €199,098
Expediting the 
diagnosis of COVID-19 
in a clinical setting 
using AI-enabled 











Dr Aaron Golden €83,690
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health needs and 
best practice for 
psychological support 
in frontline healthcare 
workers during and 
after the COVID-19 












Professor Brian McGuire €187,254
ResPoNCE: Respecting 
People with disabilities' 


























Professor Cathal O'Donoghue €38,310
EMERGE-2: a placebo 
controlled RCT of 
the Effectiveness 
of MEtformin in 
addition to usual care 









Professor Fidelma Dunne €736,569
MinDful: MusIc aNd 
Dance For Older 
adULts: The feasibility 
of an arts-based health 







Dr Amanda Clifford €378,133
SENSE-Cog Care: A 
feasibility study of 
hearing and vision 
support to improve 
quality of life in care 







Professor Iracema Leroi €402,298
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to target the blood 
pressure of older 
patients with 
hypertension – A 
cluster randomised 








Professor Andrew Murphy €399,341
Safeguarding the brain 
of our smallest children 
– an open-label phase-
III randomised trial 
of cerebral oximetry 
combined with a 
treatment guideline 
versus treatment as 







Professor Eugene Dempsey €982,646
European Blood 
Pressure Intensive 







Professor Peter Kelly €399,384
Randomised placebo-
controlled trial 
of early targeted 
treatment of patent 
ductus arteriosus 
with paracetamol 







Professor Jan Miletin €719,064














Dr Helen French €329,662
Health Research Board Annual Report 202050











trial of reduced versus 
standard volume 
platelet transfusion in 
preterm babies with 
thrombocytopenia 
(with add-on studies to 







Dr Anna Curley €1,219,599
The StrokeCog study: 
a randomised pilot 














drug Treatment in 
Elderly hospitalized 
patients (OPTIMATE): 
application of a 
definitive intervention 







Professor Denis O'Mahony €1,199,490
Enhancing Men's 
Awareness of Testicular 
Diseases (E-MAT): A 
Feasibility Study and 







Dr Mohamad Saab €391,821
Taskforce on Staffing 




Framework for Safe 
Nurse Staffing and 
Skill Mix
Professor Jonathan Drennan €1,000,000
To identify the 
underlying mechanisms 
involved in driving the 
distinct pathogenesis 
observed in PsA and 
RA, and to define 






Professor Ursula Fearon €191,309
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sequencing of inherited 
and multifactorial 
macula disease-
associated genes and 













FGE for therapeutic 







Professor Thomas Dierks €139,347
Utilising proteomics-
derived data in 
establishing predictive 
biomarker signatures 








Professor Peter O’Gorman €194,815
An investigation of 
the utility of exhaled 
breath condensate 
to detect sub-clonal 
mutations in early stage 
lung adenocarcinoma
Royal College 




Professor Bryan Hennessy €128,666










Professor Maureen O’Sullivan €188,416
Exploring diet quality 
in cystic fibrosis – 
enablers and barriers 






Dr Audrey Tierney €54,411
Including best 
practices and the 










Professor Mary McCarron €103,992
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Professor Joe Keane €65,000
Improving the 
diagnostic rate and 
prognostic value of 








Professor Gianpiero Cavalleri €194,713
First 1000 days 




Joint Program  
ming Initiative 'A 
Healthy Diet for a 
Healthy Life' 
Dr Catherine Phillips €1,382,030
Innovative plant protein 
fibre and physical 
activity solutions 
to address poor 
appetite and prevent 





Initiative 'A Healthy 
Diet for a Healthy 
Life'
Professor Clare Corish €1,189,569
PROtein enriched 
MEDiterranean diet to 
combat undernutrition 






Initiative 'A Healthy 
Diet for a Healthy 
Life' 
Professor Lorraine Brennan €681,422
Phage-based targeted 













care in a COVID-19 








Quality and Patient 
Safety
Dr Maev-Ann Wren €139,818
Sustaining increased 
and improved access 








Quality and Patient 
Safety
Dr Gráinne Cousins €103,992
Understanding and 
enhancing medication 










Quality and Patient 
Safety
Dr Michelle Flood €139,960
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An analysis of nurse-led 
COVID-19 interventions 
among homeless 






Quality and Patient 
Safety


























Dr Michael Dennedy €2,506,840
Plasma-based 









Dr Paula Bourke €4,714,652










Professor Simon Kelly €2,604,886
Social circumstances 
and epigenomics 












clinical trial by WHO: 
An international 
randomised trial of 
additional  treatments 
for COVID-19 in 
hospitalised patients 
who are all receiving 






clinical trial by 
WHO
Professor Joe Eustace €1,600,000
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CAPACITY BUILDING AND LEADERSHIP ENHANCEMENT 











Translation to Enhance 
the Use of Evidence in 
Public Health Decision-
making by Policymakers 
and Healthcare 







into Policy and 
Practice  
Dr Elaine Toomey €249,519
Food Industry Corporate 
Political Activity and its 
Potential Influence on 
Public Health Policy, 





Fellowships –  
Applying Research 
into Policy and 
Practice  
Dr Melissa Mialon €220,824








into Policy and 
Practice  
Dr Mary Walsh €214,412
Iron Deficiency 
Assessment for 







into Policy and 
Practice  
Dr Elaine McCarthy €241,040
Scenario and 
Intervention Modelling 
in Ireland for Stroke: 
Evaluating the 
effect of alternative 
policy scenarios and 
interventions for stroke 
in Ireland on outcomes 
and costs
Royal College 





into Policy and 
Practice  
Dr Eithne Sexton €227,371
Measures of wellbeing 
for use in economic 
evaluation: valuing 







into Policy and 
Practice  
Dr Irina Kinchin €244,455
Progressing Sláintecare 
delivery from proposal 
to implementation: 







into Policy and 
Practice  
Dr Bridget Johnston €240,598







Dr Martina Hayes €236,184
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data and strengthening 
health systems to 
improve outcomes in 
community emergency 







Dr Tomás Barry €470,046
Blood-based 
biomarkers for early 









Dr Emer McGrath €655,524
Exercise Therapy for 
Degenerative Meniscal 
Tears in the Primary 

































Dr Michael O'Reilly €774,703
Characterising 
problematic 









Dr Emma Wallace €774,812






Dr Ian Kelleher €774,596
Expanding the 




ex vivo lung perfusion 
and repair injured 
donor lungs
Royal College 




Professor Gerard Curley €774,760
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Precision diagnosis and 
care for families with 
pulmonary fibrosis in 
Ireland
Royal College 




Dr Killian Hurley €769,035
SUPPORT: Supporting 
PhD supervisors in 
the preparation of 
graduates for the 21st 
Century: School of 
Education, George 
Mason University (US) 







Dr Tara Cusack €15,000
Advancing the 
theoretical Model of 
Healthcare factors 
influencing Quality 
of Life in Cancer 
Survivorship (MoHaQ-








Dr Amanda Drury €9,000
Investigating the 











Dr Henry Duncan €6,000
Anaesthesiology 
Specialty Fund for PhD 
training  – supplement 
to WT ICAT, co-funded 
by  HRB and College 
of Anaesthesiology of 
Ireland (CAI)
Royal College 
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Resilience in Health 
System Performance 
and Reform Towards 
Dynamic Resilience 











Professor Steve Thomas €1,137,153
Collaboration to 
reduce antimicrobial 
use and resistance and 
identify opportunities 






















Dr Sheena McHugh €1,149,930
Improving Psychosocial 








Professor Gary Donohoe €1,149,706
Towards an integrated 
model of care for older 
adults transitioning 
from the Emergency 






Dr Rose Galvin €1,149,778
Supplemental funding 










Professor Anne Hickey €345,000
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and health care 
professionals’ 
perceptions of 
techniques to change 
health behaviour: 
what is acceptable and 






Ms Lauren O'Mahony €1,500
Assessing the stability 
of psychobiological 
stress reactivity during 
adolescence: growth 
curve modelling of 






Ms Jenna O'Shea €2,400
Examining neural tracts 
associated with the 
limbic system in vivo 
subjects with ADHD 





Mr Bernard Adegbemi €2,400
Examining Early 
Predictive Factors 






Ms Louise Howe €1,800
The Watersports 
Inclusion Games – what 






Ms Aela O'Flynn €2,400
The public health and 
economic burden of 
diabetes in middle-







Mr Patrick Walsh €1,500
Depression in Older 
Adults with Intellectual 
Disability and Epilepsy: 
findings from the 
Intellectual Disability 
Supplement to The Irish 
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and hand function 
outcomes following 
mutilating hand injuries 







Ms Ellen Geary €2,400
The Identification and 
Evaluation of a Data 
Quality Framework to 
Assess mHealth Apps 






Mr Fionn Woulfe €2,400
Assisting with the 
identification of 
adaptations to the 
Sheds for Life (SFL) 
project across 
key stakeholders 








Ms Lorraine Conneely €2,400
Investigating the 
atheroprotective role 






Mr Gavin McDaid €2,400
Mechanical Evaluation 






Miss Aliaa Karam €2,400
Precise 
Morphomolecular 








Miss May Almezen €2,400
The meso-oesophagus: 








Mr Harry Marland €2,400
Dating with a diagnosis: 
The lived experience 








Ms Kinza Tabassum €2,400
Patient-reported 








Mr Ewomazino Oderoha €2,400
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Change in weight 
between childhood 
and adolescence and 









Ms Isabel Cotter €2,400
Investigating the 
contribution of MEF2C-
regulated genes to 
different symptoms in 








Miss Muireann O'Reilly €2,400
Exploring the Student 
Nurse Experience 
of End of Life and 
Palliative Care 








Ms Sandra Murnane €2,400
A Medical perspective 
on how Virtual Reality 
can be used to assist 








Miss saoirse Hartley €1,800
Levels Of Cytokines, 
Neurotrophins And 
ApoE Genotype And 
Their Relation With 
Cognitive Disturbances 








Ms Olivia Lipsett €2,400
Clinical and functional 






Miss Ruth Walsh €2,400














Mr Padraig Donovan €2,400
Development and 
testing of the Irish 
version of the Clinical 
Learning Environment, 
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To determine whether 
expression of the novel 
IL-1 family members IL-
37 and IL-38 cytokines 
represent potential 






Mr Samuel Keogh €2,400
Developing a priority 
setting partnership 








Mr Ao Lik Lee €2,400
INFRASTRUCTURE AND NETWORKS










HRB Clinical Research 
Coordination Ireland 









Professor Joseph Eustace €848,842
HRB Clinical Research 
Coordination 
Ireland 2020 – CRCI 
Coordination Costs
University 





Professor Joseph Eustace €205,000
HRB Clinical Research 
Coordination Ireland 
2020 – Outreach Site: 
NCRC
Royal College 






Professor Paul McNally €47,156
HRB Clinical Research 
Coordination Ireland 









Professor Martin O'Donnell €68,413
HRB Clinical Research 
Coordination Ireland 
2020 – Outreach Site: 
RCSI
Royal College 
of Surgeons in 





Professor Dermot Kenny €113,551
HRB Clinical Research 
Coordination Ireland 








Professor Martina Hennessy €71,250
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HRB Clinical Research 
Coordination Ireland 
2020 – Outreach Site: 
UCC
University 





Professor Joseph Eustace €73,225
HRB Clinical Research 
Coordination Ireland 








Professor Peter Doran €137,196
HRB Clinical Research 
Coordination Ireland 








Dr Rachel Msetfi €62,749
Transition funding for 
CTI for 2021 to allow 
time for design and 








Professor Linda Coate €3,561,620
Supplemental funding 
for the HRB-CTN in 
Critical Care to support 
their participation in 
an international clinical 








Professor Alistair Nichol €400,000




HRCI Core Support Dr Avril Keenan €300,000













Dr Derick Mitchell €300,000
AIIHPC Palliative Care 
Research Network 
(previously SRN) – 
supplement for an 
additional two 0.5 FTE 







Ms Karen Charnley €210,000







Professor Sean Dinneen €4,900,000
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HRB co-funded awards
Scheme Co-funding partner Co-funding 
allocation
Total award HRB share
Applied Partnership 
Awards





Nursing & Midwifery Planning & 
Development Unit, HSE South 











HSE Quality Improvement division 










Health Service ExecutiveHealth 




COVID-19 Rapid Response 
Research, Development 
and Innovation programme
Irish Research Council (Strand 3) €138,355 €138,355 €0
COVID-19 Rapid Response 
Research, Development 
and Innovation programme
Irish Research Council (Strand 3) €125,139 €125,139 €0
COVID-19 Rapid Response 
Research, Development 
and Innovation programme
Irish Research Council (Strand 3) €198,693 €198,693 €0
COVID-19 Rapid Response 
Research, Development 
and Innovation programme
Irish Research Council (Strand 3) €63,350 €63,350 €0
Applied Partnership 
Awards





Nursing & Midwifery Planning & 
Development Unit, HSE South 
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HRB co-funded awards
Scheme Co-funding partner Co-funding 
allocation
Total award HRB share




Applied Partnership Awards HSE Quality Improvement 
division and National Office of 
Clinical Audit
€40,000 €239,998 €199,998
Applied Partnership Awards Spina Bifida Hydrocephalus 
Ireland
€25,000 €148,188 €123,188
Applied Partnership Awards Health Service ExecutiveHealth 




COVID-19 Rapid Response 
Research, Development and 
Innovation programme
Irish Research Council (Strand 3) €138,355 €138,355 €0
COVID-19 Rapid Response 
Research, Development and 
Innovation programme
Irish Research Council (Strand 3) €125,139 €125,139 €0
COVID-19 Rapid Response 
Research, Development and 
Innovation programme
Irish Research Council (Strand 3) €198,693 €198,693 €0
COVID-19 Rapid Response 
Research, Development and 
Innovation programme
Irish Research Council (Strand 3) €63,350 €63,350 €0
COVID-19 Rapid Response 
Research, Development and 
Innovation programme
Irish Research Council (Strand 3) €180,727 €180,727 €0
COVID-19 Rapid Response 
Research, Development and 
Innovation programme
Irish Research Council (Strand 3) €194,299 €194,299 €0
COVID-19 Rapid Response 
Research, Development and 
Innovation programme
Irish Research Council (Strand 3) €191,116 €191,116 €0
COVID-19 Rapid Response 
Research, Development and 
Innovation programme
Irish Research Council (Strand 3) €175,013 €175,013 €0
COVID-19 Rapid Response 
Research, Development and 
Innovation programme
Irish Research Council (Strand 3) €134,455 €134,455 €0
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HRB co-funded awards
Scheme Co-funding partner Co-funding 
allocation
Total award HRB share
COVID-19 Rapid Response 
Research, Development and 
Innovation programme
Irish Research Council (Strand 3) €111,040 €111,040 €0
COVID-19 Rapid Response 
Research, Development and 
Innovation programme
Irish Research Council (Strand 3) €175,322 €175,322 €0
COVID-19 Rapid Response 
Research, Development and 
Innovation programme
Irish Research Council (Strand 3) €123,370 €123,370 €0
COVID-19 Rapid Response 
Research, Development and 
Innovation programme
Irish Research Council (Strand 3) €117,574 €117,574 €0
COVID-19 Rapid Response 
Research, Development and 
Innovation programme
Irish Research Council (Strand 3) €148,745 €148,745 €0
COVID-19 Rapid Response 
Research, Development and 
Innovation programme
Irish Research Council (Strand 3) €185,340 €185,340 €0
COVID-19 Rapid Response 
Research, Development and 
Innovation programme
Irish Research Council (Strand 3) €66,394 €66,394 €0
COVID-19 Rapid Response 
Research, Development and 
Innovation programme
Irish Research Council (Strand 3) €202,382 €202,382 €0
COVID-19 Rapid Response 
Research, Development and 
Innovation programme
Irish Research Council (Strand 3) €199,945 €199,945 €0
COVID-19 Rapid Response 
Research, Development and 
Innovation programme
Irish Research Council (Strand 3) €152,847 €152,847 €0
COVID-19 Rapid Response 
Research, Development and 
Innovation programme
Irish Research Council (Strand 3) €187,254 €187,254 €0
COVID-19 Rapid Response 
Research, Development and 
Innovation programme
Irish Research Council (Strand 3) €199,952 €199,952 €0
COVID-19 Rapid Response 
Research, Development and 
Innovation programme
Irish Research Council (Strand 3) €38,310 €38,310 €0
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HRB co-funded awards
Scheme Co-funding partner Co-funding 
allocation
Total award HRB share
Irish Clinical Academic 
Training
College of Anaesthesiology of 
Ireland 
€500,000 €1,000,000 €500,000
HRCI-HRB Joint Funding 
Scheme 
Centre for Arthritis and 
Rheumatic Diseases
€95,655 €191,309 €95,655
HRCI-HRB Joint Funding 
Scheme 
Fighting Blindness €97,500 €195,000 €97,500
HRCI-HRB Joint Funding 
Scheme 
MSD Action Foundation €69,674 €139,347 €69,674
HRCI-HRB Joint Funding 
Scheme 
Breakthrough Cancer Research €97,408 €194,815 €97,408
HRCI-HRB Joint Funding 
Scheme 
Breakthrough Cancer Research €64,333 €128,666 €64,333
HRCI-HRB Joint Funding 
Scheme 
Breakthrough Cancer Research €94,208 €188,416 €94,208
HRCI-HRB Joint Funding 
Scheme 
Cystic Fibrosis Ireland €27,206 €54,411 €27,206
HRCI-HRB Joint Funding 
Scheme 
The Alzheimer Society of Ireland €51,996 €103,992 €51,996
HRCI-HRB Joint Funding 
Scheme 
Irish Thoracic Society €32,500 €65,000 €32,500
HRCI-HRB Joint Funding 
Scheme 
Irish Nephrology Society €97,357 €194,713 €97,357
Joint Programming Initiative 
'A Healthy Diet for a Healthy 
Life'
Joint Programming Initiative 'A 
Healthy Diet for a Healthy Life' 
€1,015,780 €1,382,030 €366,250
Joint Programming Initiative 
Healthy Diet for a Healthy 
Life
Joint Programming Initiative 'A 
Healthy Diet for a Healthy Life' 
€823,527 €1,189,569 €366,042
Joint Programming Initiative 
'A Healthy Diet for a Healthy 
Life'
Joint Programming Initiative 'A 
Healthy Diet for a Healthy Life' 
€446,350 €681,422 €235,072
Joint Programming Initiative 
in Neurodegenerative 
Diseases
JPND €1,213,193 €1,583,192 €369,999
AIIHPC Structured Research 
Network
Health and Social Care R&D 
Division, Northern Ireland 
€105,000 €210,000 €105,000
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HRB co-funded awards
Scheme Co-funding partner Co-funding 
allocation
Total award HRB share
PPI National Network Irish Research Council and 
Network Lead Sites
€2,600,000 €4,900,000 €2,300,000
Research Collaborative in 
Quality and Patient Safety
Department of Health €69,910 €139,818 €69,908
Research Collaborative in 
Quality and Patient Safety
Health Service Executive 
Addiction Services
€51,996 €103,992 €51,996
Research Collaborative in 
Quality and Patient Safety
Health Service Executive Quality 
Improvement Team
€69,980 €139,960 €69,980
Research Collaborative in 
Quality and Patient Safety
Safetynet Primary Care €60,628 €121,255 €60,627
US-Ireland Research and 
Development Partnership 
Award
SFI and the National Institutes of 
Health (USA)
€2,965,685 €3,406,729 €441,044
US-Ireland Research and 
Development Partnership 
Award
SFI and the National Institutes of 
Health (USA)
€2,053,731 €2,506,840 €453,109
US-Ireland Research and 
Development Partnership 
Award
SFI and the National Institutes of 
Health (USA)
€4,305,675 €4,714,652 €408,977
US-Ireland Research and 
Development Partnership 
Award
SFI and the National Institutes of 
Health (USA)
€2,229,330 €2,604,886 €375,777
US-Ireland Research and 
Development Partnership 
Award
SFI and the National Institutes of 
Health (USA)
€3,421,245 €3,835,762 €414,517
Solidarity international trial 
by WHO
Department of Health €1,600,000 €1,600,000 €0
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The Corporate Governance and Financial 
Statements information will be published in  
a Part 2 to this document upon receipt of the 
audited financial statements from the Office  
of the Comptroller and Auditor General.
Corporate Governance 
and Financial Statements 
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